Drug Approval | February 26, 2022
Japan approves Keytruda plus Lenvima for two types of cancer
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
In the interim, Deepak Khanna will lead Human Health International.
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
They will commercialize molnupiravir in the international markets
The brand is now available pan-India through their distribution partner
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
A toll-free helpline to be set up to help doctors and patients
Subscribe To Our Newsletter & Stay Updated
